Please be aware that this site uses cookies
More information
Research News

Breast Cancer Research News

Classe JM et al. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French Prospective Multicentric Study. J Clin Oncol. 2008 Dec 29. [Epub ahead of print]

Classe JM and colleagues investigated the detection rate, the false-negative rate, and the accuracy of sentinel lymph node (SLN) detection after neoadjuvant chemotherapy (NC) for advanced breast cancer. 195 patients enrolled from 12 institutions were recruited to a prospective multi-centre study. The authors observed that the detection rate was 90% (176 of 195 patients), and the false-negative rate was 11.5% (6 of 52 patients). Patients without axillary palpable nodes (N0) before NAC had a better detection rate compared with patients with axillary suspicious nodes (N1, 94.6% v 81.5%; P = 0.008). The false-negative rate was not correlated with clinical nodal status before NC (9.4% v 15%; P =0.66). This study confirms the feasibility of SLN biopsy after NC in locally-advanced operable breast cancer. The detection rate, false-negative rate, and accuracy are similar to those reported for early breast cancer without NC.